Novo Nordisk's insulin degludec injection is now available in pharmacies nationwide.
Novo Nordisk’s insulin degludec injection (Tresiba) is now available in pharmacies nationwide.
The once-daily, long-acting basal insulin was approved in September 2015 for improving glycemic control in adults with diabetes.
"When developing new therapies, Novo Nordisk keeps patients' needs top of mind,” said Camille Lee, senior vice president of Diabetes Marketing at Novo Nordisk, in a press release. “With its long-acting blood glucose lowering effect, lasting for at least 42 hours, Tresiba is a shining example of that. We're proud to offer this new treatment for adults living with diabetes and are excited to see the impact it may have on management of their blood sugar."
Tresiba is an insulin therapy that releases over time and lasts a minimum of 42 hours after 8 once-daily injections. This allows patients to take a dose at any time of day.
If patients miss a dose, they should take the missed dose if at least 8 hours have elapsed between consecutive injections.
It is not recommended for the treatment of diabetic ketoacidosis, and it is not known if it is safe or effective in children under the age of 18 years.
Adverse effects associated with Tresiba include itching, rash or swelling at the injection site, weight gain, and swelling of the hands or feet.
Severe adverse effects include low blood sugar, low potassium levels, and heart failure. These symptoms may manifest as anxiety, irritability, and dizziness. Patients should seek medical attention immediately if they notice these symptoms.